Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-25wd4 Total loading time: 0 Render date: 2024-04-29T23:46:19.864Z Has data issue: false hasContentIssue false

20 - Physical health and metabolic dysfunction in bipolar disorder

Published online by Cambridge University Press:  05 May 2016

By
Joshua D. Rosenblat ,
Danielle S. Cha ,
Rodrigo B. Mansur  and
Roger S. McIntyre
Edited by
Jair C. Soares  and
Allan H. Young
Jair C. Soares
Affiliation:
University of Texas Health Science Center, Houston
Allan H. Young
Affiliation:
King's College London
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Bipolar Disorders
Basic Mechanisms and Therapeutic Implications
 , pp. 256 - 268
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ahmed, A.T., Blair, T.R., McIntyre, R.S. Surgical treatment of morbid obesity among patients with bipolar disorder: a research agenda. Adv Ther. 2011;28(5):389–400.CrossRefGoogle Scholar
Ahmed, A.T., Warton, E.M., Schaefer, C.A., et al. The effect of bariatric surgery on psychiatric course among patients with bipolar disorder. Bipolar Disord. 2013;5(7):753–63.Google Scholar
Akhondzadeh, S., Jafari, S., Raisi, F., et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26(7):607–11.CrossRefGoogle ScholarPubMed
Allison, D.B., Mentore, J.L., Heo, M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–96.CrossRefGoogle ScholarPubMed
Alsuwaidan, M.T., Kucyi, A., Law, C.W. et al. Exercise and bipolar disorder: a review of neurobiological mediators. Neuromol Med. 2009;11(4):328–36.CrossRefGoogle ScholarPubMed
Al-Zoairy, R., Ress, C., Tschoner, A., et al. The effects of psychotropic drugs on the regulation of glucose metabolism. Curr Diabetes Rev. 2013;9(5):362–70.CrossRefGoogle ScholarPubMed
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists & North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601.CrossRefGoogle Scholar
Bai, Y.M., Chen, J.Y., Chen, T.T., et al. Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients. Schizophr Res. 2009;108(1–3):122–6.CrossRefGoogle ScholarPubMed
Basson, B.R., Kinon, B.J., Taylor, C.C., et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 2001;62(4):231–8.CrossRefGoogle ScholarPubMed
Beavers, K.M., Brinkley, T.E., Nicklas, B.J. Effect of exercise training on chronic inflammation. Clin Chim Acta. 2010;411(11–12):785–93.CrossRefGoogle ScholarPubMed
Berk, M., Dean, O., Drexhage, H., et al. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med. 2013;11 :74-7015-11-74.CrossRefGoogle Scholar
Bobes, J., Rejas, J., Garcia-Garcia, M., et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res. 2003;62(1–2):77–88.CrossRefGoogle ScholarPubMed
Bobo, W.V. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Exp Rev Clin Pharmacol. 2013;6(1):61–91.CrossRefGoogle ScholarPubMed
Boden, R., Haenni, A., Lindstrom, L. et al. Biochemical risk factors for development of obesity in first-episode schizophrenia. Schizophr Res. 2009;115(2–3):141–5.CrossRefGoogle ScholarPubMed
Brietzke, E., Mansur, R.B., Soczynska, J.K., et al. Towards a multifactorial approach for prediction of bipolar disorder in at risk populations. J Affect Disord. 2012;140(1):82–91.CrossRefGoogle ScholarPubMed
Brydon, L., Walker, C., Wawrzyniak, A., et al. Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav Immun. 2009;23(2):217–24.CrossRefGoogle ScholarPubMed
Capuron, L., Ravaud, A., Gualde, N., et al. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology. 2001;26(8):797–808.CrossRefGoogle ScholarPubMed
Capuron, L., Ravaud, A., Neveu, P.J., et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry. 2002;7(5):468–73.CrossRefGoogle ScholarPubMed
Capuron, L., Neurauter, G., Musselman, D.L., et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54(9):906–14.Google Scholar
Chwieduk, C.M., Scott, L.J. Asenapine: a review of its use in the management of mania in adults with bipolar I disorder. CNS Drugs. 2011;25(3):251–67.CrossRefGoogle ScholarPubMed
Citrome, L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27(11):879–911.CrossRefGoogle ScholarPubMed
Citrome, L. Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf. 2014;13(6):803–30.Google ScholarPubMed
Citrome, L., Ketter, T.A., Cucchiaro, J. et al. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2014;155:20–7.CrossRefGoogle ScholarPubMed
Coderre, L., Srivastava, A.K., Chiasson, J.L. Role of glucocorticoid in the regulation of glycogen metabolism in skeletal muscle. Am J Physiol. 1991;260(6):E927–32.Google ScholarPubMed
Correll, C.U., Frederickson, A.M., Kane, J.M. et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res. 2007;89(1–3):91–100.CrossRefGoogle ScholarPubMed
Covic, T., Cumming, S.R., Pallant, J.F., et al. Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the Depression, Anxiety and Stress Scale (DASS) and the Hospital, Anxiety and Depression Scale (HADS). BMC Psychiatry. 2012;12:6-244X-12–6.CrossRefGoogle ScholarPubMed
Cutler, A.J., Kalali, A.H., Weiden, P.J., et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28(2)(Suppl 1):S20–8.CrossRefGoogle ScholarPubMed
De Hert, M., Correll, C.U., Bobes, J., et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52–77.CrossRefGoogle ScholarPubMed
Dunn, A.J., Swiergiel, A.H., de Beaurepaire, R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev. 2005;29(4–5):891–909.CrossRefGoogle ScholarPubMed
Ekdahl, C.T. Microglial activation – tuning and pruning adult neurogenesis. Frontiers Pharmacol. 2012;3:41.CrossRefGoogle ScholarPubMed
Emerging Risk Factors Collaboration Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.Google Scholar
Fagiolini, A., Frank, E., Scott, J.A., et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005;7(5):424–30.CrossRefGoogle ScholarPubMed
Fiocco, A.J., Scarcello, S., Marzolini, S., et al. The effects of an exercise and lifestyle intervention program on cardiovascular, metabolic factors and cognitive performance in middle-aged adults with type II diabetes: a pilot study. Can J Diabetes. 2013;37(4):214–19.CrossRefGoogle ScholarPubMed
Frol, A.B., Vasquez, A., Getahun, Y., et al. A comparison of clinician-rated neuropsychological and self-rated cognitive assessments in patients with asthma and rheumatologic disorders. Allergy Asthma Proc. 2013;34(2):170–5.CrossRefGoogle ScholarPubMed
Gans, R.O. The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms. Med Clin North Am. 2006;90(4):573–91.CrossRefGoogle ScholarPubMed
Gebhardt, S., Haberhausen, M., Heinzel-Gutenbrunner, M., et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res. 2009;43(6)620–6.CrossRefGoogle Scholar
Gilles, M., Wilke, A., Kopf, D., et al. Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: implications for atypical antipsychotics. Psychosomat Med. 2005;67(5):748–51.CrossRefGoogle ScholarPubMed
Giralt, M., Villarroya, F. White, brown, beige/brite: different adipose cells for different functions? Endocrinology. 2013;154(9):2992–3000.CrossRefGoogle Scholar
Girgis, R.R., Javitch, J.A., Lieberman, J.A. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry. 2008;13(10):918–29.CrossRefGoogle ScholarPubMed
Goldstein, B.I., Kemp, D.E., Soczynska, J.K. et al. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70(8):1078–90.CrossRefGoogle ScholarPubMed
Graff, L.A., Walker, J.R., Bernstein, C.N. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis. 2009;15(7):1105–18.CrossRefGoogle ScholarPubMed
Grigoleit, J.S., Kullmann, J.S., Wolf, O.T., et al. Dose-dependent effects of endotoxin on neurobehavioral functions in humans. PloS One. 2011;6(12):e28330.CrossRefGoogle ScholarPubMed
Grundy, S.M., Cleeman, J.I., Merz, C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720–32.CrossRefGoogle ScholarPubMed
Harrison, N.A., Brydon, L., Walker, C., et al. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry. 2009;66(5):407–14.CrossRefGoogle ScholarPubMed
Hart, B.L. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev. 1988;12(2):123–37.CrossRefGoogle ScholarPubMed
Heffner, J.L., Strawn, J.R., DelBello, M.P., et al. The co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations. Bipolar Disord. 2011;13(5–6):439–53.CrossRefGoogle ScholarPubMed
Hoyer, S., Henneberg, N., Knapp, S., et al. Brain glucose metabolism is controlled by amplification and desensitization of the neuronal insulin receptor. Ann N Y Acad Sci. 1996;777:374–9.CrossRefGoogle ScholarPubMed
James, P.T., Rigby, N., Leach, R. et al. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prevent Rehabil. 2004;11(1):3–8.CrossRefGoogle ScholarPubMed
Janney, C.A., Fagiolini, A., Swartz, H.A., et al. Are adults with bipolar disorder active? Objectively measured physical activity and sedentary behavior using accelerometry. J Affect Disord. 2014;152–154:498–504.CrossRefGoogle ScholarPubMed
Kaidanovich-Beilin, O., Cha, D.S., McIntyre, R.S. Crosstalk between metabolic and neuropsychiatric disorders. F1000 Biol Rep. 2012;4:14.CrossRefGoogle ScholarPubMed
Kan, C., Silva, N., Golden, S.H., et al. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care. 2013;36(2):480–9.CrossRefGoogle ScholarPubMed
Karunakaran, U., Park, K.G. A systematic review of oxidative stress and safety of antioxidants in diabetes: focus on islets and their defense. Diabetes Metab J. 2013;37(2):106–12.CrossRefGoogle ScholarPubMed
Katon, W., von Korff, M., Ciechanowski, P., et al. Behavioral and clinical factors associated with depression among individuals with diabetes. Diabetes Care. 2004;27(4):914–20.CrossRefGoogle ScholarPubMed
Kilbourne, A.M., Rofey, D.L., McCarthy, J.F., et al. Nutrition and exercise behavior among patients with bipolar disorder. Bipolar Disord. 2007;9(5):443–52.CrossRefGoogle ScholarPubMed
Kim, B., Kim, S.J., Son, J.I. et al. Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord. 2008;105(1–3):45–52.CrossRefGoogle ScholarPubMed
Kraft, A.D., Harry, G.J. Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health. 2011;8(7):2980–3018.CrossRefGoogle ScholarPubMed
Krakowski, M., Czobor, P., Citrome, L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res. 2009;110(1–3):95–102.CrossRefGoogle ScholarPubMed
Lee, S.Y., Park, M.H., Patkar, A.A. et al. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35(2):490–6.CrossRefGoogle ScholarPubMed
Leucht, S., Cipriani, A., Spineli, L., et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.CrossRefGoogle ScholarPubMed
Loebel, A., Cucchiaro, J., Silva, R., et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160–8.Google ScholarPubMed
Martinsen, E.W. Physical activity in the prevention and treatment of anxiety and depression. Nordic J Psychiatry. 2008;62(Suppl 47):25–9.CrossRefGoogle ScholarPubMed
McElroy, S.L., Keck, P.E.,Jr Obesity in bipolar disorder: an overview. Curr Psychiatry Rep. 2012;14(6):650–8.CrossRefGoogle ScholarPubMed
McElroy, S.L., Kotwal, R., Malhotra, S., et al. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry. 2004;65(5):634–51, quiz 730.CrossRefGoogle ScholarPubMed
McIntyre, R.S. Asenapine: a review of acute and extension phase data in bipolar disorder. CNS Neurosci Ther. 2011;17(6):645–8.CrossRefGoogle ScholarPubMed
McIntyre, R.S., McCann, S.M., Kennedy, S.H. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001;46(3):273–81.CrossRefGoogle ScholarPubMed
McIntyre, R.S., Konarski, J.Z., Soczynska, J.K., et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization Psychiatr Serv. 2006;57(8):1140–4.CrossRefGoogle ScholarPubMed
McIntyre, R.S., Soczynska, J.K., Konarski, J.Z., et al. Should depressive syndromes be reclassified as ”metabolic syndrome type II”? Ann Clin Psychiatry. 2007;19(4):257–64.CrossRefGoogle ScholarPubMed
McIntyre, R.S., Vagic, D., Swartz, S.A., et al. Insulin, insulin-like growth factors and incretins: neural homeostatic regulators and treatment opportunities. CNS Drugs. 2008;22(6):443–53.CrossRefGoogle ScholarPubMed
McIntyre, R.S., Danilewitz, M., Liauw, S.S., et al. Bipolar disorder and metabolic syndrome: an international perspective.J Affect Disord. 2010;126(3):366–87.CrossRefGoogle ScholarPubMed
McIntyre, R.S., Soczynska, J.K., Woldeyohannes, H.O, et al. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disord. 2012;14(7):697–706.CrossRefGoogle ScholarPubMed
McIntyre, R.S., Cha, D.S., Kim, R.D. et al. A review of FDA-approved treatment options in bipolar depression. CNS Spectrums. 2013;18(Suppl 1):4–20; quiz 21.CrossRefGoogle ScholarPubMed
McNamara, R.K., Lotrich, F.E. Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target? Exp Rev Neurother. 2012;12(9):1143–61.CrossRefGoogle ScholarPubMed
McNay, E.C., Recknagel, A.K. Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol Learn Memory. 2011;96(3):432–42.Google Scholar
McQuade, R., Young, A.H. Future therapeutic targets in mood disorders: the glucocorticoid receptor. Br J Psychiatry. 2000;177:390–5.CrossRefGoogle ScholarPubMed
Meyer, J.M. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63(5):425–33.CrossRefGoogle ScholarPubMed
Miller, A.H., Maletic, V., Raison, C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732–41.CrossRefGoogle ScholarPubMed
Morrato, E.H., Newcomer, J.W., Allen, R.R. et al. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry. 2008;69(2):316–22.CrossRefGoogle ScholarPubMed
Morriss, R., Mohammed, F.A. Metabolism, lifestyle and bipolar affective disorder. J Psychopharmacol. 2005;19(6)(Suppl):94–101.CrossRefGoogle ScholarPubMed
Nery, F.G., Monkul, E.S., Hatch, J.P., et al. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol. 2008;23(2):87–94.CrossRefGoogle ScholarPubMed
Ng, F., Mammen, O.K., Wilting, I., et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009;11(6):559–95.CrossRefGoogle ScholarPubMed
Osby, U., Brandt, L., Correia, N., et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844–50.CrossRefGoogle ScholarPubMed
Pace, T.W., Miller, A.H. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci. 2009;1179:86–105.CrossRefGoogle ScholarPubMed
Paradise, M.B., Naismith, S.L., Norrie, L.M., et al. The role of glia in late-life depression. Int Psychogeriatr / IPA. 2012;24(12):1878–90.CrossRefGoogle ScholarPubMed
Raison, C.L., Broadwell, S.D., Borisov, A.S., et al. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav Immun. 2005;19(1):23–7.CrossRefGoogle ScholarPubMed
Raison, C.L., Rutherford, R.E., Woolwine, B.J., et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31–41.CrossRefGoogle ScholarPubMed
Reichenberg, A., Yirmiya, R., Schuld, A., et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58(5):445–52.CrossRefGoogle ScholarPubMed
Reininghaus, E.Z., McIntyre, R.S., Reininghaus, B., et al. Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2014;16(4):432–40.CrossRefGoogle ScholarPubMed
Roerig, J.L., Steffen, K.J., Mitchell, J.E. Atypical antipsychotic-induced weight gain: insights into mechanisms of action, CNS Drugs. 2011a;25(12):1035–59.CrossRefGoogle ScholarPubMed
Roerig, J.L., Steffen, K.J., Mitchell, J.E. Atypical antipsychotic-induced weight gain: insights into mechanisms of action, CNS Drugs. 2011b;25(12):1035–59.CrossRefGoogle ScholarPubMed
Romo-Nava, F., Alvarez-Icaza Gonzalez, D., Fresan-Orellana, A., et al. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial. Bipolar Disord. 2014;16(4):410–21.CrossRefGoogle ScholarPubMed
Rosamond, W., Flegal, K., Friday, G., et al. Heart disease and stroke statistics – 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115(5):e69–171.CrossRefGoogle ScholarPubMed
Rosenblat, J.D., Cha, D.S., Mansur, R.B., et al. Inflamed moods: A review of the interactions between inflammation and mood disorders. Prog Neuro- Psychopharmacol Biol Psychiatry. 2014;53C:23–34.CrossRefGoogle Scholar
S Roriz-Filho, J., Sa-Roriz, T.M., Rosset, I., et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta. 2009;1792(5):432–43.Google ScholarPubMed
Saddichha, S., Ameen, S., Akhtar, S. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol. 2008;28(1):27–31.CrossRefGoogle ScholarPubMed
Safer, D.J. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol. 2004;24(4):429–36.CrossRefGoogle ScholarPubMed
Soczynska, J.K., Kennedy, S.H., Woldeyohannes, H.O., et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromol Med. 2011;13(2):93–116.CrossRefGoogle ScholarPubMed
Stertz, L., Magalhaes, P.V., Kapczinski, F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr Opin Psychiatry. 2013;26(1):19–26.CrossRefGoogle ScholarPubMed
Strassnig, M., Miewald, J., Keshavan, M., et al. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res. 2007;93(1–3):90–8.CrossRefGoogle ScholarPubMed
Strike, P.C., Wardle, J., Steptoe, A. Mild acute inflammatory stimulation induces transient negative mood. J Psychosom Res. 2004;57(2):189–94.CrossRefGoogle ScholarPubMed
Sugimoto, Y., Yoshikawa, T., Yamada, J. Effects of peripheral administration of 5-hydroxytryptamine (5-HT) on 2-deoxy-D-glucose-induced hyperphagia in rats. Biol Pharm Bull. 2002;25(10):1364–6.CrossRefGoogle ScholarPubMed
Swartz, H.A., Fagiolini, A. Cardiovascular disease and bipolar disorder: risk and clinical implications. J Clin Psychiatry. 2012;73(12):1563–5.CrossRefGoogle ScholarPubMed
Topp, R., Fahlman, M., Boardley, D. Healthy aging: health promotion and disease prevention. Nurs Clin North Am. 2004;39(2):411–22.CrossRefGoogle ScholarPubMed
Tran, B., Oliver, S., Rosa, J. et al. Aspects of inflammation and oxidative stress in pediatric obesity and type 1 diabetes: an overview of ten years of studies. Exp Diabetes Res. 2012;2012:683680.CrossRefGoogle Scholar
Tulipano, G., Rizzetti, C., Bianchi, I., et al. Clozapine- induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic–pituitary–adrenal axis activation. Neuroendocrinology. 2007;85(2):61–70.CrossRefGoogle ScholarPubMed
Vancampfort, D., Vansteelandt, K., Correll, C.U., et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013a;170(3):265–74.CrossRefGoogle ScholarPubMed
Vancampfort, D., Vansteelandt, K., Correll, C.U., et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013b;170(3):265–74.CrossRefGoogle ScholarPubMed
Walker, J.R., Graff, L.A., Dutz, J.P., et al. Psychiatric disorders in patients with immune-mediated inflammatory diseases: prevalence, association with disease activity, and overall patient well-being. J Rheumatol Suppl. 2011;88:31–5.CrossRefGoogle ScholarPubMed
WHO 2013a. Diabetes Fact Sheet. Available: http://www.who.int/mediacentre/factsheets/fs312/en/ (accessed 10 May 2014).Google Scholar
WHO 2013b. Obesity and Overweight Fact Sheet. Available: http://www.who.int/mediacentre/factsheets/fs311/en/ (accessed 10 2014).Google Scholar
Wright, C.E., Strike, P.C., Brydon, L. et al. Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun. 2005;19(4):345–50.CrossRefGoogle ScholarPubMed
Young, A.H., Grunze, H. Physical health of patients with bipolar disorder. Acta Psychiatr Scand Suppl. 2013;442:3–10.CrossRefGoogle ScholarPubMed
Zhang, Q., Lian, J., He, M., et al. Olanzapine reduced brown adipose tissue thermogenesis and locomotor activity in female rats. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;51:172–80.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×